Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-10-06

FDA Approved: TURALIO — Supplemental Application (Daiichi Sankyo Inc.)

View source ↗

Summary

The FDA approved a supplemental application for TURALIO (pexidartinib hydrochloride) submitted by Daiichi Sankyo Inc., resulting in updated labeling and/or indi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TURALIO (pexidartinib)

Snippet

SUPPL AP for TURALIO (PEXIDARTINIB HYDROCHLORIDE)